MedTrace Logo

Identification of Integrin ab Expression in Lung Cancer Patients

NCT06167941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2023-12-13

No results posted yet for this study

Summary

It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ3 and ανβ5 antagonist has been widely used for targeting various cancers including NSCLC, glioblastoma, and colon carcinoma as well as prostate cancer. In this study, the investigators aim to analysis the expression of integrin ανβ3 in lung cancer patients.

Conditions

  • Expression of Integrin ανβ3 in Lung Cancer

Interventions

BIOLOGICAL

Lung cancer types

Cancer tissue matched to normal tissue, all from the same patient

Sponsors & Collaborators

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Hyun Koo Kim · Korea University Guro Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-19
Primary Completion
2021-09-10
Completion
2021-11-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06167941 on ClinicalTrials.gov